InMed Pharmaceuticals Inc. is a biopharmaceutical company. The Company develops cannabis-based botanical and non-botanical therapies through research and development into the extensive pharmacology of cannabinoids. InMed Pharmaceuticals focuses on its proprietary platform technology, drug discovery, and commercialization development.

424B3 | Prospectus

S-1/A | IPO Registration (Amendment)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

InMed Pharmaceuticals (INM US)

424B3 | Prospectus

S-1/A | IPO Registration (Amendment)

S-1 | IPO Registration

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2024-12-18)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)